Pages that link to "Q40853140"
Jump to navigation
Jump to search
The following pages link to SUMATRIPTAN: a receptor-targeted treatment for migraine (Q40853140):
Displaying 50 items.
- Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers (Q24676273) (← links)
- Evidence-Based Treatments for Adults with Migraine (Q26769968) (← links)
- Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines (Q28379537) (← links)
- Neuroendocrine signaling modulates specific neural networks relevant to migraine (Q30842243) (← links)
- The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation (Q33535327) (← links)
- Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials (Q34154647) (← links)
- Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input (Q34276405) (← links)
- Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study (Q34393819) (← links)
- Magnesium taurate and fish oil for prevention of migraine (Q34410787) (← links)
- Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery (Q34548443) (← links)
- Contemporary concepts of migraine pathogenesis (Q35569299) (← links)
- Headache and facial pain in children and adolescents (Q35693014) (← links)
- Where do triptans act in the treatment of migraine? (Q35748273) (← links)
- Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers (Q35936959) (← links)
- Migraine: current concepts and emerging therapies (Q36229186) (← links)
- Unitary hypothesis for multiple triggers of the pain and strain of migraine (Q36301292) (← links)
- Migraine and patent foramen ovale: A residual coincidence or a pathophysiological intrigue? (Q36473672) (← links)
- Migraine: emerging treatment options for preventive and acute attack therapy (Q36580576) (← links)
- Diagnosis and management of migraine (Q36598581) (← links)
- Migraine in multiple sclerosis (Q36832908) (← links)
- Menstrual migraine: a review of hormonal causes, prophylaxis and treatment (Q36904875) (← links)
- Emerging therapies for migraine (Q36992954) (← links)
- The change of neutrophils/lymphocytes ratio in migraine attacks: A case-controlled study (Q37172630) (← links)
- Current and prospective pharmacological targets in relation to antimigraine action (Q37216396) (← links)
- Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study (Q37785552) (← links)
- CGRP and its receptors provide new insights into migraine pathophysiology (Q37785745) (← links)
- Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study (Q37827498) (← links)
- Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment (Q37996578) (← links)
- Acute treatment of migraines (Q38028610) (← links)
- Multiple sclerosis and pain (Q38036427) (← links)
- QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case (Q38065274) (← links)
- Pathophysiological mechanisms of headache in patients with HIV. (Q38204789) (← links)
- An update on migraine: current understanding and future directions. (Q38742593) (← links)
- Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA. (Q39117083) (← links)
- Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience (Q39471681) (← links)
- Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache (Q39485720) (← links)
- The triptans (Q39983756) (← links)
- Dietary Migraine: Recent Progress in the Red (And White) Wine Story (Q40463275) (← links)
- Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions (Q40970990) (← links)
- Current concepts of the pathophysiology of migraine (Q41371780) (← links)
- Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. (Q41974492) (← links)
- Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres. (Q42073244) (← links)
- Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan (Q43262227) (← links)
- 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity? (Q43543016) (← links)
- 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses (Q43621340) (← links)
- Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex (Q43836509) (← links)
- Persistence of attacks of cluster headache after trigeminal nerve root section (Q43964370) (← links)
- Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine. (Q44282545) (← links)
- Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination (Q45131483) (← links)
- A trans-cultural comparison of the organisation of care at headache centres world-wide. (Q45250723) (← links)